Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

TZA reported for 6 months of 2023

7/13/23 TUZA

Delta Air Lines reported for 6 months of 2023

7/13/23 DAL

Pepsico has reported for 6 months of 2023

7/13/23 PEP

Slavneft-Yaroslavnefteorgsintez reported for 6 months of 2023 by RAS

7/13/23 JNOS

Varioganneftegaz reported for 6 months of 2023 by RAS

7/13/23 VJGZ

MTS received 16% in Primo RPA business process robotization platform

7/13/23 MTSS

Segezha Group opened a representative office in China

7/12/23 SGZH

NLMK brings its plant in India to full capacity

7/12/23 NLMK

VSMPO-AVISMA to build a long product rolling complex for ₽21 billion

7/12/23 VSMO

Ozon will invest ₽8 billion to create a logistics hub in Saratov

7/12/23 OZON